Blocking angiotensin ii type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells

Pancreas

Volumn 39, Issue 5, 2010, Pages 581-594

  Gong, Qiaoke ^a   Davis, Molly ^a   Chipitsyna, Galina ^a   Yeo, Charles J ^a   Arafat, Hwyda A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

angiotensin II; apoptosis; losartan; p53; pancreatic cancer

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; LOSARTAN; MESSENGER RNA; MUTANT PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BAX PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE; GENETICS; METABOLISM; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, PANCREATIC DUCTAL; CASPASE 3; CELL LINE, TUMOR; HUMANS; LOSARTAN; MUTATION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ANGIOTENSIN, TYPE 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954129591     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181c314cd     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Arnold NB, Arkus N, Gunn J, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res. 2007;13:18-26.
3. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg. 2003;186:279-286.
4. Caponigro F, Formato R, Caraglia M, et al. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. Curr Opin Oncol. 2005;17:212-217.
5. Abrams RA. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma. Semin Oncol. 2005;32:S30-S32
6. De Gasparo M, Catt KJ, Inagami T, et al. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
7. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179-184.
8. Reddy MK, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med. 1995;210:221-226.
9. Arafat HA, Gong Q, Chipitsyna G, et al. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg. 2007;204:996-1005.
10. Anandanadesan R, Gong Q, Chipitsyna G, et al. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg. 2008;12:57-66.
11. Sipos B, Möser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003;442:444-452.
12. Sohn TA, Bansal R, Su GH, et al. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002;23:949-957.
13. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am. 1998;4(3):194-203.
14. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun. 2002;294:441-447.
15. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest. 2003;112:67-75.
16. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62:4176-4179.
17. Lam KY, Leung PS. Regulation and expression of a renin-angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol. 2002;146:567-572.
18. Ohta T, Amaya K, Yi S, et al. Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol. 2003;23:593-598.
19. Fujimoto Y, Sasaki T, Tsuchida A, et al. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001;495: 197-200.
20. Liu WB, Wang XP, Wu K, et al. Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. World J Gastroenterol. 2005; 11:6489-6494.
21. Kim H, Yoon SC, Lee TY, et al. Discriminative cytotoxicity assessment based on various cellular damages. Toxicol Lett. 2009;184:13-17.
22. Redondo-Müller MA, Stevanovic-Walker M, et al. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer. 2008;15:277-288.
23. Chu KY, Lau T, Carlsson PO, et al. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55:367-374.
24. Chu KY, Leung PS. Angiotensin II Type 1 receptor antagonism mediates uncoupling protein 2-driven oxidative stress and ameliorates pancreatic islet beta-cell function in young type 2 diabetic mice. Antioxid Redox Signal. 2007;9(7):869-878.
25. Levin A. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
26. Appleman LJ, Frey AB. Dominant-negative p53 can restore tumorigenicity of L-929 cells in immunocompetent mice. Int J Cancer. 1995;63:576-583.
27. Koliopanos A, Avgerinos C, Paraskeva C, et al. Molecular aspects of carcinogenesis in pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2008;7:345-356.
28. his). Oncogene. 1996;12:715-725.
29. Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998;292:435-445.
30. Blagosklonny MV. Loss of function and p53 protein stabilization. Oncogene. 1997;15:1889-1893.
31. Gross A, Jockel J, Wei MC, et al. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17:3878-3885.
32. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998;281:2027-2031.
33. Antonsson B, Conti F, Ciavatta A, et al. Inhibition of Bax channel-forming activity by Bcl-2. Science. 1997;277:370-372.
34. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
35. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature. 1994;369:321-323.
36. T. Hsu T, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A. 1997;94:3668-3672.
37. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer. 2003;2:6.
38. Xu ZW, Friess H, Buchler MW, et al. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol. 2002;49:504-510.
39. Seki T, Ohba N, Makino R, et al. Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene, Anticancer Res. 2001;21:1919-1924.
40. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis, Oncogene. 2000;19:5477-5486.
41. Pierzchalski P, Reiss K, Cheng W, et al. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res. 1997;234:57-65.
42. Leri A, Claudio PP, Li Q, et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest. 1998;101:1326-1342.
43. Haupt Y, Rowan S, Shaulian E, et al. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 1995;9: 2170-2183.
44. Kakudo Y, Shibata H, Otsuka K, et al. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s. Cancer Res. 2005;65: 2108-2114.
45. Nunez G, Benedict MA, Hu Y, et al. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17:3237-3245.
46. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897-907.
47. Kobayashi D, Sasaki M, Watanabe N. Caspase-3 activation downstream from reactive oxygen species in heat-induced apoptosis of pancreatic carcinoma cells carrying a mutant p53 gene. Pancreas. 2001;22: 255-260.